Objectives: In a prospective multicenter study, we evaluated the effects of switching from an alpha-blocker to tadalafil on lower urinary tract symptoms (LUTS) and sexual function in patients with benign prostatic hyperplasia (BPH).Methods: The inclusion criteria for enrollment into the study were as follows: 1) treatment with an alpha-blocker for BPH for > 3 months at screening, and 2) International Prostate Symptom Score (IPSS) of ≥ 8. The alpha-blocker was switched to tadalafil at a dose of 5 mg once daily without a washout period. Self-reported questionnaires regarding the IPSS-Quality of Life (QOL) score, the Overactive Bladder Symptom Score (OABSS), the International Index of Erectile Function 5 (IIEF5), and the Medical Outcome Study 8-Item Short-Form Health Survey (SF-8) were completed by the patients. These measures were assessed at the baseline and again after 4, 8, and 12 weeks of tadalafil therapy. Uroflowmetry was also performed at the baseline and again at the 12-week end-point visit. Results: Thirty patients with a mean age of 69.4 years were enrolled. In total, 26 patients were eligible for the analysis. After switching from an alpha-blocker to tadalafil, total IPSS, voiding subscore, QOL index, IIEF5, and role limitations because of emotional problems and mental health scores in the SF-8 were found to have significantly improved after 4∼12 weeks of tadalafil therapy. However, the IPSS storage subscore, the OABSS total score, nocturia, and uroflowmetry parameters were found to be unchanged. There were no serious adverse events. Conclusions: Tadalafil at a dose of 5 mg once daily may be effective in patients with BPH/LUTS who are resistant to alpha-blockers.
|Number of pages||8|
|Journal||Nishinihon Journal of Urology|
|Publication status||Published - Aug 2016|
All Science Journal Classification (ASJC) codes